Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Brief report

Utility of mouth rinses with povidone-iodine and hydrogen peroxide in patients with COVID-19

Daniel Pablo-Marcos a, Beatriz Abascal b, Lara Lloret c, Manuel Gutiérrez Cuadra b, Nieves Velasco d, Carmen Valero b, e

a Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain
b Departamento de Medicina Interna, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain
c Instituto de Física de Cantabria, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain
d Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain

Keywords: Mouth/rinses Povidone-iodine Coronavirus Hydrogen peroxide Load viral

ABSTRACT

Introduction: Povidone-iodine and hydrogen peroxide could be effective in against SARS-CoV-2.
Methods: A “non-interventional trial” in 88 patients (43 ± 17 yrs., 55% men) with SARS-CoV-2 in nasopharyngeal swabs (RT-PCR). 31 received mouth rinses/gargling with povidone-iodine (every 8h, two consecutive days), 17 with mouth rinses/gargling of hydrogen peroxide, and 40 controls. Were repeated PCR in 3, 11 and 17 days.
Results: After intervention the viral load (Log10 copies/ml) remained similar in povidone-iodine (4.3 ± 2.7 copies/ml), hydrogen peroxide (4.6 ± 2.9 copies/ml; p = 0.40) and controls (4.4 ± 3.0 copies/ml). The percentage of patients with a negative result in the second PCR was 27% in povidone-iodine group, 23% in hydrogen peroxide and 32% in controls; in the third PCR, 62%, 54% and 58% respectively; and in the fourth PCR, 81%, 75% and 81%.
Conclusion: Our results do not support the clinical usefulness of mouth rinses/gargling with povidone-iodine or hydrogen peroxide in patients with COVID-19.

© 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.
Introduction

The oral cavity plays an important role in the transmission of SARS-CoV-2. The oral mucosal epithelial cells express ACE-2 receptors and the salivary glands are a reservoir for the virus. For this reason, various scientific societies have proposed the use of antiseptic oral solutions to reduce transmission. Povidone-iodine (PVI) has already shown significant in vitro antiviral activity against MERS and SARS-CoV. and more recently against SARS-CoV-. Hydrogen peroxide (H2O2) is also effective against SARS-CoV-2 on inanimate surfaces and in cell cultures. However, the in vivo efficacy of either oral antiseptic has not been clarified in this pandemic. Therefore, we aim to determine the utility of mouth rinses and gargles with PVI and H2O2 in reducing the oropharyngeal viral load of SARS-CoV-2 in patients with COVID-19.

Materials and methods

This was an observational prospective follow-up study (EPAAS), classified by the Spanish Agency of Medicines and Medical Devices (AEMPS), in 88 patients (inpatients or outpatients) with COVID-19 confirmed by RT-PCR in nasopharyngeal samples (Ct <35 N or R gene; VIASURE SARS-CoV-2 Real Time PCR Detection Kit, Certest, Zaragoza, Spain). The patients were diagnosed at our hospital between May and November 2020. Patients under 18 years of age, patients with a decreased level of consciousness, presence of mouth ulcers or wounds, thyroid diseases, hypersensitivity to PVI or hydrogen peroxide, who were pregnant or breast-feeding or on treatment with lithium, were excluded. Inclusion in the study occurred less than 24 h after the first positive PCR determination. Of the 88 patients (mean age 43 ± 17 years, range 19-86 years, 55% male), 31 carried out PVI (1%) oral solution rinses and gargarises every 8 h (100 mg/ml; 30 s) for 2 consecutive days; 17 carried out rinses and gargarises with H2O2 (1.5%) with the same regimen and 40 were part of the control group without rinses or gargarises. After the intervention, PCR was performed after 3 (2-4), 11 (9-13) and 17 (14-19) days in all patients.

SARS-CoV-2 viral load was measured by quantitative PCR in all determinations (qRT-PCR; EDX SARS-CoV-2 Standard; Exact Diagnostics, Bio-Rad; E, N, ORF1a, RdRP and S genes). The viral load was expressed as Log10 of the mean of the viral loads of both genes (N and R) and Ct values. The processing of the samples and the interpretation of the results was a blinded study. Serological studies (IgG) were performed by chemiluminescence immunoassay (Vir-CIA, Monotest, Virccell, S.L., Granada, Spain).

Informed consent was requested and the study was approved by the Cantabrian Medicines Research Ethics Committee.

The results were expressed as the mean and standard deviation (SD) for the quantitative variables and n (%) for the qualitative variables. The Kolmogorov–Smirnov test was used to determine the distribution of the variable. The Student’s T-test or Mann–Whitney U test was used for the comparison of quantitative variables and the Chi-squared or Fisher’s test was used for qualitative variables. The SPSS 23.0 software statistical package was used (Chicago, IL, USA). Statistical significance was considered to be p < 0.05.

Results

Two thirds of the patients were seen on an outpatient basis (76%). The 3 groups began with the same viral load in the first positive PCR (PVI 6.4 ± 2.0 copies/ml, H2O2 7.5 ± 2.1 copies/ml and controls 6.8 ± 2.2 copies/ml). There were no differences in viral load after rinses in the second determination (PVI 4.3 ± 2.7 copies/ml, H2O2 4.6 ± 2.9 copies/ml and controls 4.4 ± 3.0 copies/ml). Neither were there differences in the third and fourth successive PCR determinations (Table 1). The Ct values (N and R gene) were similar in the 3 groups at all times (Table 1).

The percentage of patients whose PCR was negative in the second determination was 27% in PVI, 23% in H2O2 and 26% in controls. These percentages were similar in the third PCR (62%, 54%, and 58%) and fourth PCR (81%, 75%, and 81%, respectively) (Fig. 1).

There were no differences in the immune response. 87% of the patients with PVI rinses developed immunoglobulin G, compared to 82% in H2O2 and 95% in the controls (mean time of 74 ± 31, 78 ± 33 and 81 ± 48 days, respectively).

Discussion

PVI and H2O2 rinses and gargarises did not change the oropharyngeal viral load of patients with COVID-19. These oral antiseptics did not accelerate the neutralisation of the PCR for SARS-CoV-2. PVI is an iodophor that owes its antiviral action to free iodine, altering cell membranes and protein synthesis. However, its recognised in vitro activity against SARS-CoV-2 does not seem to be evident in vivo, although we only found one clinical trial in this regard, conducted in 12 patients with COVID-19 who after receiving rinses and gargarises with PVI (1%) did not have a modified oropharyngeal viral load of SARS-CoV-2 compared to the untreated group. Furthermore, H2O2 has also shown efficacy in vitro in inactivating SARS-CoV-2, albeit less effectively than PVI. Its antiviral potency seems to be due to oxidation. To date, the use of this antiseptic in

| Table 1 |
|-----------------|-----------------|-----------------|
| Virus load in the 3 groups. | | |
| | Controls n = 40 | PVI n = 31 | H2O2 n = 17 |
| Log10 copies/ml | | | |
| Baseline PCR | 6.8 (2.2) | 6.4 (2.0); p = 0.38 | 7.5 (2.1); p* = 0.24 |
| 2nd PCR | 4.4 (3.0) | 4.3 (2.7); p = 0.93 | 4.6 (2.9); p* = 0.84 |
| 3rd PCR | 2.4 (2.4) | 1.7 (1.8); p = 0.40 | 2.1 (2.5); p* = 0.16 |
| 4th PCR | 1.1 (1.6) | 1.0 (1.7); p = 0.91 | 1.8 (2.5); p* = 0.40 |
| Ct N gene | | | |
| Baseline PCR | 26.8 (6.5) | 27.7 (6.3); p = 0.62 | 26.4 (6.2); p* = 0.72 |
| 2nd PCR | 32.7 (7.4) | 32.7 (7.0); p = 0.99 | 33.1 (7.0); p* = 0.70 |
| 3rd PCR | 37.6 (5.4) | 39.7 (3.7); p = 0.27 | 39.5 (5.4); p* = 0.10 |
| 4th PCR | 40.3 (3.4) | 40.3 (3.8); p = 0.96 | 39.8 (5.6); p* = 0.40 |
| Ct R gene | | | |
| Baseline PCR | 26.3 (7.9) | 27.0 (7.8); p = 0.68 | 24.9 (7.8); p* = 0.53 |
| 2nd PCR | 32.4 (8.4) | 32.2 (7.6); p = 0.91 | 33.5 (8.6); p* = 0.45 |
| 3rd PCR | 38.0 (6.1) | 39.6 (3.8); p = 0.88 | 40.4 (5.5); p* = 0.06 |
| 4th PCR | 41.3 (2.9) | 40.5 (3.9); p = 0.33 | 40.0 (5.8); p* = 0.36 |

Mean (SD) or n (%).

Ct: cycle threshold; RT-PCR: real-time polymerase chain reaction.

Mann–Whitney: p (PVI and controls); p* (H2O2 and controls).
COVID-19 patients has been a matter of great debate.\textsuperscript{15,16} Our work is the first observational study with a control group that evaluates the utility of H\textsubscript{2}O\textsubscript{2} mouth rinses in COVID-19 patients and we do not see a clear reduction in viral load in the short or in the medium term.

We only found one other study, without a control group, in 12 hospitalised COVID-19 patients who received H\textsubscript{2}O\textsubscript{2} (1\%) mouth rinses, with no change in their oropharyngeal viral load at 30 min.\textsuperscript{17}

Our study has limitations, as it is not randomised. However, we included a large number of patients with a control group and evaluated the utility of two commonly used oral antiseptics.

We conclude that rinses and gargles of PVI and H\textsubscript{2}O\textsubscript{2} do not seem to have a clear utility in reducing the oropharyngeal viral load of SARS-CoV-2. We believe that the recommendation for the use of these and other oral antiseptics should be based on scientific evidence, hence more studies are needed to assess their efficacy in this pandemic.

Funding

This work was financed with a Research Grant awarded by the Consejo Superior de Investigaciones Científicas [Spanish National Research Council] (CSIC. 202050E106). Spain.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Acknowledgements

To the Spanish National Research Council and Javier Xercavins, from the Ministry of Science and Innovation. To professors Jesús Agüero and J.A. Riancho (University of Cantabria), Spain.

References

1. Meselson M. Droplets and aerosols in the transmission of SARS-CoV-2. N Engl J Med. 2020;382:2063.
2. Liu J, Lao X, Qian S, Yuan J, Wang F, Liu Y, et al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. 2020;26:1320–3. http://dx.doi.org/10.3201/eid2606.200239.
3. Baghizadeh Fini M. Oral saliva and COVID-19. Oral Oncol. 2020;108:104821. http://dx.doi.org/10.1016/j.oraloncology.2020.104821.
4. Yan CH, Bleier BS. Prophylactic and therapeutic topical povidone-iodine in coronavirus disease 2019 (COVID-19): What is the evidence? Int Forum Allergy Rhinol. 2020;10:1271–3. http://dx.doi.org/10.1002/alr.22735.
5. Vargas-Buratovic JP, Verdugo-Paiva F, Vélez-Paiva C, López-Tagle E, Ahumada-Salinas A, Ortuño-Borroto D. Dental recommendations in the COVID-19 pandemic: a narrative review. Medwave. 2020;20:e7916. http://dx.doi.org/10.5867/medwave.2020.05.7916.
6. Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against middle east respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus ankara (MVA). Infect Dis Ther. 2015;4:491–501.
7. Kariwa H, Fuji N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions, and chemical reagents. Jpn J Vet Res. 2004;52:105–12.
8. Anderson DE, Sivalingam V, Zheng Kang AE, Ananthanarayanan A, Arumugam H, Jenkins TM, et al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect Dis Ther. 2020;9:669–75. http://dx.doi.org/10.1007/s40121-020-00316-3.
9. Kampf G, Todt D, Pfländer S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104:246–51. http://dx.doi.org/10.1016/j.jhin.2020.01.022.
10. Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Comparison of in vitro inactivation of SARS CoV-2 with hydrogen peroxide and povidone-iodine oral antiseptic rinses. J Prosthodont. 2020;29:599–603. http://dx.doi.org/10.1111/jopr.13220.
11. Guezezan J, Garcia M, Strasters D, Jousselin C, Lévêque N, Frasca D, Mimoz O. Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2021;4:e2005490. http://dx.doi.org/10.1001/jamaoto.2020.5490.
12. Sriwijiaraojen N, Wilaiait P, Hiramatsu H, Takahashi T, Suzuki T, Ito Y, et al. Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J. 2009;6:124.
13. Maximilian J, Gottsauner IM, Schmidt B, Scholz KJ, Buchalla W, Widhiller M, et al. A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2. Clin Oral Investig. 2020;24:3707–13. http://dx.doi.org/10.1007/s00784-020-03549-1.
14. Liu M, Chen F, Liu T, Chen F, Liu S, Yang J. The role of oxidative stress in influenza virus infection. Microbes Infect. 2017;19:580–6. http://dx.doi.org/10.1016/j.micinf.201708008.
15. Caruso AA, del Prete A, Lazzarino AI. Hydrogen peroxide and viral infections: a literature review with research hypothesis definition in relation to the current covid-19 pandemic. Med Hypotheses. 2020;144:109910. http://dx.doi.org/10.1016/j.mehy.2020.109910.
16. Ortega KL, Rech BO, El Haje GLC, Gallo CB, Pérez-Sayáns M, Braz-Silva PH. Do hydrogen peroxide mouthwashes have a virucidal effect? A systematic review. J Hosp Infect. 2020;106:657–62. http://dx.doi.org/10.1016/j.jhin.2020.10.003.